DLD Asset Management’s Biogen BIIB Stock Holding History

DLD Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-346,800	Closed	-$82M	–	93
2019 Q1	$82M	Buy	+346,800	New	+$109M	3.02%	10

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DLD Asset Management's BIIB Position: Q2 2019 in Review

DLD Asset Management sold out of Biogen (BIIB) in Q2 2019, closing a stake of 346,700 shares — an estimated $82M sold.

DLD Asset Management first reported a position in BIIB in Q1 2019 and held it in 1 quarter. The position peaked at $82M in Q1 2019. 1,010 funds tracked by Wall St. Rank hold BIIB as of Q2 2019.

DLD Asset Management reported no remaining Biogen position as of Q2 2019 after selling out during the quarter.
DLD Asset Management sold 346,700 Biogen shares in Q2 2019, an estimated $82M.
DLD Asset Management first reported a position in Biogen in Q1 2019 and held it in 1 quarter.
DLD Asset Management's Biogen position peaked at $82M in Q1 2019.
1,010 funds tracked by Wall St. Rank held Biogen as of Q2 2019.

Based on DLD Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.